PEN Earnings Prediction
The chart below shows how PEN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PEN sees a +2.80% change in stock price 10 days leading up to the earnings, and a +5.08% change 10 days following the report. On the earnings day itself, the stock moves by -0.46%. This data can give you a slight idea of what to expect for the next quarter's release.
PEN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
315.52M
10.83%
4.81%
Gross Margin
66.79%
1.67%
0.38%
Operating Margin
13.56%
10.24%
1.19%
Net Margin
10.68%
-43.94%
8.87%
EPS
0.82
-40.58%
9.33%
No Data Available
PEN Earnings Analysis
Penumbra Inc Corporation (PEN.N) Earnings Conference Call
Positive
Earnings Per Share Beat: Penumbra, Inc. reported an EPS of $0.97, exceeding expectations of $0.88, indicating strong financial performance.
Revenue Growth Analysis: In Q4 2024, revenue reached $321.3 million, reflecting a year-over-year growth of 12.9% on an adjusted basis and 13% on a constant currency basis.
Thrombectomy Sales Surge: The U.S. thrombectomy business saw significant growth, with sales increasing 27.3% year-over-year to $180.6 million, driven by the CAVT portfolio's strong performance.
Revenue Increase Overview: For the full year 2024, total revenue increased 13.4% year-over-year to over $1.2 billion, with the U.S. thrombectomy business delivering a 26.8% increase to $646.7 million.
Gross Margin Improvement: Gross margin improved to 67.4%, up 170 basis points from the prior year, showcasing enhanced profitability.
Q4 Operating Income Increase: Operating income for Q4 was $48.6 million, or 15.1% of revenue, an increase of 200 basis points over the prior year period, indicating operational efficiency.
Strong Cash Flow Management: The company generated $49.1 million in operating cash in Q4, reflecting strong cash flow management.
Product Portfolio Expansion: Penumbra introduced 9 new products to the U.S. market in 2024, enhancing its product portfolio and market competitiveness.
Gross Margin Improvement: The company is on track to achieve a gross margin profile over 70% by the end of 2026, indicating a positive outlook for profitability.
VTE Revenue Surge: Penumbra's U.S. VTE franchise reported robust year-over-year revenue growth of 41%, highlighting strong market demand.
Negative
International Revenue Decline: International revenue decreased 9.4% adjusted and 9.1% in constant currency, primarily due to a decline in China revenue of $15.4 million.
Gross Margin Analysis: The full year gross margin was 63.4%, which includes a one-time $33.4 million Immersive Healthcare inventory write-off, compared to 64.5% of revenue for the full year of 2023.
Decline in Adjusted EBITDA: Adjusted EBITDA in 2024 was $171 million or 14.2% of total revenue compared to 16.1% last year, indicating a decline in profitability.
Operating Expenses Analysis: Operating expenses for Q4 2024 were $167.9 million or 52.3% of revenue, which is a slight increase from 52.5% of revenue in Q4 2023, indicating rising costs.
Italian Payback Legislation Impact: The company faced a $5.8 million reserve related to Italian payback legislation, which could impact future financial performance.
Inventory Write-Off Impact: The winding down of the Immersive Healthcare business resulted in a one-time inventory write-off of $33.4 million, affecting overall profitability.
PEN FAQs
How does PEN typically perform around its earnings report dates?
Is Penumbra Inc (PEN) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PEN Earning Call Sentiment
Penumbra, Inc. (NYSE:PEN) Q4 2024 Earnings Call Transcript
PEN.N
-2.43%Positive
While the earnings call highlighted strong financial performance and growth, concerns were raised over litigation expenses, business transition risks, and lack of clarity in future guidance. The Q&A revealed uncertainty about product timelines and market assumptions, particularly in China, which tempers enthusiasm. The absence of a share repurchase program and the impact of a one-time inventory write-off also weigh on sentiment. Overall, the mixed signals suggest a neutral market reaction.
